Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population

Table 1

Clinicopathological and molecular characteristics of the study.

	Patients ( (%))
Demographic characteristics
Median age, years	56 (28-81)
Gender
Female	25 (43.9)
Male	32 (56.1)
Age
<50	23 (40.4)
≥50	34 (59.6)
Clinicopathological characteristics
Location of tumor
High	5 (8.8)
Middle	26 (45.6)
Low	26 (45.6)
Type of neoadjuvant treatment
Chemoradiotherapy	39 (68.4)
Radiotherapy	18 (31.6)
Surgical procedure
Abdominoperineal excision	10 (17.5)
Anterior resection	47 (82.5)
R0/R1 status
R0	52 (91.2)
R1	5 (8.8)
Histologic type
Adenocarcinoma	54 (94.7)
Mucinous carcinoma/signet ring carcinoma	3 (5.3)
Degrees of differentiation
Well	29 (50.9)
Moderate	25 (43.9)
Poor/undifferentiated	3 (5.3)
Therapeutic response according to the percentage of tumor regression
<50%	21 (36.8)
≥50%	36 (63.2)
Therapeutic response according to Dworak
Complete response	7 (12.3)
Incomplete response	50 (87.7)
Dworak
1	8 (14)
2	20 (35.1)
3	22 (38.6)
4	7 (12.3)
Perineural invasion
Yes	7 (12.3)
No	50 (87.7)
Vascular invasion
Yes	5 (8.8)
No	52 (91.2)
ypN
N0	38 (66.7)
N+	19 (33.3)
ypT
T0	7 (12.3)
T1	3 (5.3)
T2	21 (36.8)
T3	25 (43.9)
T4	1 (1.8)
Survival
Death	5 (8.8)
Lost to follow-up/alive	52 (91.2)
Local and distant relapse
No	36 (63.2)
Yes	21 (36.8)
Molecular characteristics
Ki67
<50	18 (31.6)
≥50	39 (68.4)
MSI
Stable	23 (40.4)
Unstable	11 (19.3)
BRAF exon 15 (V600E)
Wild type	47 (100)
Mutated	0 (0)
KRAS 2
Wild type	41 (71.9)
Mutated	16 (28.1)
HER-2 scoring
0	43 (75.4)
1	8 (14)
2	3 (5.3)
3	3 (5.3)
p53
<20	6 (10.5)
20-50	8 (14)
≥50	43 (75.4)